Market Access/ News/ News Praluent approved to reduce CV risk in Europe George Underwood Amgen, cardiovascular, CV, Praluent, Regeneron, Repatha, Sanofi 0 Comment The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share X Praluent approved to reduce CV risk in Europe https://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Amgen, cardiovascular, CV, Praluent, Regeneron, Repatha, Sanofi
0 Comment
